Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395784 · ClinicalTrials.gov registry record · Phase 2
Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01395784 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 32 participants.
The verdict
NCT01395784, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The ability of pioglitazone (PIO) to alter the effects of opioids in humans has not been characterized in a controlled laboratory setting. Accordingly, the proposed investigation seeks to examine the effects of PIO on oxycodone, one of the most commonly used and abused opioid drugs in the U.S. (Davis et al., 2003). More specifically, the primary aim of this investigation is to characterize the subjective effects of oxycodone under maintenance on various doses of PIO (0, 15, and 45 mg) in non-dependent, prescription opioid abusers. Secondary aims of the study are to examine the influence of PIO on the analgesic, cognitive, and physiological effects of oxycodone.
Interventions
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-08 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01395784
The ClinicalTrials.gov registry entry for NCT01395784 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pioglitazone is the first listed.
NCT01395784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01395784 about?
NCT01395784 is a clinical study titled "Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone". The ability of pioglitazone (PIO) to alter the effects of opioids in humans has not been characterized in a controlled laboratory setting. Accordingly, the proposed investigation seeks to examine the effects of PIO on oxycodone, one of the most commonly used and abused opioid drugs in the U.S. (Davi...
What is the current status of trial NCT01395784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2010-08. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01395784?
The interventions under investigation include: pioglitazone (DRUG).
Who is sponsoring clinical trial NCT01395784?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.